CTLA4 and neoplasm: Furthermore, these studies also identify a unique anti-tumor resistance in Mertk-/- V1 mice against anti-CTLA-4 and anti-PD-1 refractory YUMM1.7 melanoma as well as against GL261 brain tumors, the molecular basis of which remains unknown.